MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in MiNK Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −2 vs. Q2 2022
- Shares held
- 475.7K
- +118.3K (+33.1%) vs. Q2 2022
- Total value
- $1.00M
- +$499.0K (+99.0%) vs. Q2 2022
- New holders
- 5
- 2 more added
- Sold out
- 7
- 1 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $2.39M |
| Q1 2026 | 23 | $1.34M |
| Q4 2025 | 25 | $1.71M |
| Q3 2025 | 18 | $1.28M |
| Q2 2025 | 19 | $460.8K |
| Q1 2025 | 17 | $544.2K |
| Q4 2024 | 23 | $564.9K |
| Q3 2024 | 26 | $632.3K |
| Q2 2024 | 31 | $847.8K |
| Q1 2024 | 34 | $848.1K |
| Q4 2023 | 36 | $1.05M |
| Q3 2023 | 36 | $800.0K |
| Q2 2023 | 45 | $3.10M |
| Q1 2023 | 12 | $1.15M |
| Q4 2022 | 16 | $1.70M |
| Q3 2022 | 11 | $1.00M |
| Q2 2022 | 13 | $504.0K |
| Q1 2022 | 25 | $1.76M |
| Q4 2021 | 21 | $5.96M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding MiNK Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Artal Group S.A. | 289,588 | $611.0K | 0.03% | 00.0% | Unchanged |
| First Republic Investment Management, Inc. | 81,500 | $172.0K | 0.00% | +81,500 | New |
| Vanguard Group Inc | 49,107 | $104.0K | 0.00% | +49,107 | New |
| Geode Capital Management, LLC | 23,175 | $48.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 11,109 | $23.0K | 0.00% | +11,109 | New |
| HighTower Advisors, LLC | 10,400 | $22.0K | 0.00% | +10,400 | New |
| BlackRock Inc. | 10,005 | $21.0K | 0.00% | +3,366+50.7% | Added |
| UBS Group AG | 258 | $1.00K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 468 | $1.00K | 0.00% | +468 | New |
| Morgan Stanley | 42 | $0 | 0.00% | −421−90.9% | Reduced |
| Wells Fargo & Company | 31 | $0 | 0.00% | +9+40.9% | Added |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −35,500−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,104−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −374−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −247−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −21−100.0% | Sold out |